Generics
Nexus Pharmaceuticals wins FDA approval for Succinylcholine Chloride Injection, USP
30 October 2020 -

Healthcare company Nexus Pharmaceuticals reported on Thursday the receipt of approval from the US Food and Drug Administration (FDA) for Succinylcholine Chloride Injection, USP in 200mg/10ml Multiple-Dose Vials.

Succinylcholine Chloride Injection, USP is AP-rated generic to QUELICIN, a registered trademark of Hospira Inc. It is a sterile, nonpyrogenic solution to be used as an ultra-short-acting, depolarizing, skeletal muscle relaxant.

Succinylcholine is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

This critical need drug has seen increased demand due to the COVID-19 pandemic.

Nexus will supply Succinylcholine Chloride Injection, USP in cartons of 25 vials.

Login
Username:

Password:


Related Headlines